These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28415595)

  • 1. 18F-Fluoride PET/CT tumor burden quantification predicts survival in breast cancer.
    Brito AE; Santos A; Sasse AD; Cabello C; Oliveira P; Mosci C; Souza T; Amorim B; Lima M; Ramos CD; Etchebehere E
    Oncotarget; 2017 May; 8(22):36001-36011. PubMed ID: 28415595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.
    Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A
    Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.
    Etchebehere EC; Araujo JC; Fox PS; Swanston NM; Macapinlac HA; Rohren EM
    J Nucl Med; 2015 Aug; 56(8):1177-84. PubMed ID: 26069307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the Semiautomatic Quantification of
    Brito AE; Mourato F; Santos A; Mosci C; Ramos C; Etchebehere E
    J Nucl Med Technol; 2018 Dec; 46(4):378-383. PubMed ID: 30076246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT.
    Rohren EM; Etchebehere EC; Araujo JC; Hobbs BP; Swanston NM; Everding M; Moody T; Macapinlac HA
    J Nucl Med; 2015 Oct; 56(10):1507-12. PubMed ID: 26135112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy.
    Etchebehere EC; Araujo JC; Milton DR; Erwin WD; Wendt RE; Swanston NM; Fox P; Macapinlac HA; Rohren EM
    Clin Nucl Med; 2016 Apr; 41(4):268-73. PubMed ID: 26828141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
    Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
    Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of skeletal tumour burden on 18F-NaF PET/CT using a new quantitative method.
    Lapa P; Marques M; Costa G; Iagaru A; Pedroso de Lima J
    Nucl Med Commun; 2017 Apr; 38(4):325-332. PubMed ID: 28230714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer.
    Jo JE; Kim JY; Lee SH; Kim S; Kang T
    Acta Radiol; 2015 Dec; 56(12):1463-70. PubMed ID: 25406431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of 18F-Sodium Fluoride PET/CT Bone Scans in the Diagnosis of Metastatic Bone Disease from Breast and Prostate Cancer.
    Kulshrestha RK; Vinjamuri S; England A; Nightingale J; Hogg P
    J Nucl Med Technol; 2016 Dec; 44(4):217-222. PubMed ID: 27634981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT.
    Petrén-Mallmin M; Andréasson I; Ljunggren O; Ahlström H; Bergh J; Antoni G; Långström B; Bergström M
    Skeletal Radiol; 1998 Feb; 27(2):72-6. PubMed ID: 9526771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma.
    Chakraborty D; Bhattacharya A; Mete UK; Mittal BR
    Clin Nucl Med; 2013 Aug; 38(8):616-21. PubMed ID: 23603596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
    Du Y; Cullum I; Illidge TM; Ell PJ
    J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.
    Hahn S; Heusner T; Kümmel S; Köninger A; Nagarajah J; Müller S; Boy C; Forsting M; Bockisch A; Antoch G; Stahl A
    Acta Radiol; 2011 Nov; 52(9):1009-14. PubMed ID: 21969709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients.
    Yen RF; Chen CY; Cheng MF; Wu YW; Shiau YC; Wu K; Hong RL; Yu CJ; Wang KL; Yang RS
    Nucl Med Commun; 2010 Jul; 31(7):637-45. PubMed ID: 20389259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Extension study and evaluation of the therapeutic response in a patient with metastatic lung adenocarcinoma using sequential study with ¹⁸F-FDG PET-CT and ¹⁸F-fluoride PET-CT].
    Moragas M; Soler M; Riera E; García JR
    Rev Esp Med Nucl Imagen Mol; 2015; 34(1):45-8. PubMed ID: 24690280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of metastatic bone lesions in breast cancer patients: fused (18)F-Fluoride-PET/MDCT has higher accuracy than MDCT. Preliminary experience.
    Piccardo A; Altrinetti V; Bacigalupo L; Puntoni M; Biscaldi E; Gozza A; Cabria M; Iacozzi M; Pasa A; Morbelli S; Villavecchia G; DeCensi A
    Eur J Radiol; 2012 Oct; 81(10):2632-8. PubMed ID: 22227259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
    Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
    Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.